Outstanding Interim Results for Zylox-Tonbridge
Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190), a leader in medical technology, has recently reported its interim results for the mandated reporting period. The company witnessed remarkable revenue growth of 31.7%, reaching RMB 482 million, while net profit soared by 76.0% to exceed RMB 121 million, marking a net profit margin of 25.1%.
Core Business Performance
The first half of the year highlighted strong performance in both neurovascular and peripheral vascular intervention sectors. Specifically, neurovascular product revenue hit RMB 304 million, reflecting a 25% increase from the prior year. Furthermore, peripheral vascular products saw significant growth, with revenue rising to RMB 176 million, or 46.2% year-over-year.
Operational Efficiency
Zylox-Tonbridge has adeptly managed to decrease combined R&D, selling, and administrative expenses as a percentage of revenue by 7 percentage points. This focus on operational efficiency has effectively enhanced the company’s profitability profile.
International Business Expansion
The company’s international operations continue to thrive, contributing RMB 15.72 million in revenue during the first half of the year. By the reporting date, Zylox-Tonbridge had successfully commercialized 22 products across 27 countries, with additional products under registration in 23 markets. The expansion of its global network to 52 countries through collaborations with over 60 local distributors positions the company for sustained growth.
Innovative Product Launches
Zylox-Tonbridge's diverse and high-quality product portfolio has facilitated strong sales growth throughout the year. The company successfully renewed several products under a stable procurement environment, reinforcing its market share. Notable products include the SilverSnake Intermediate Catheter Series, Kylin Flow Diverter, and the UltraFree Drug-Coated PTA Balloon Catheter.
Advancing Innovative Solutions
While focusing on mature products, the company is committed to innovative solutions that address clinical needs. Recently approved products include the ZYLOX Eagle Aspiration System and the TONBRIDGE Shunfeng Balloon Vascular Closure Device, which bolster their product lineup. Additionally, exciting new products aimed at addressing complex medical challenges are anticipated to gain approval soon.
Addressing Clinical Challenges
Among the forthcoming innovations is the Mammoth Peripheral Large Lumen Thrombus Aspiration Catheter, envisioned as a solution for deep vein thrombosis with its unique design. In the neurovascular domain, a novel self-expanding aneurysm embolization device is in development, promising enhanced treatment for challenging cases of wide-neck bifurcation aneurysms.
Global Growth Strategy
The strategic investment in international research and development has proven fruitful for Zylox-Tonbridge. Their products have achieved market penetration in seven of the top ten medical device markets worldwide, including France, Germany, and Italy. The emerging markets of Brazil, India, and South Africa also showcase substantial growth opportunities.
Regulatory Approvals and Market Participation
Recent regulatory successes include approvals in Indonesia for the ZYLOX Unicorn Vascular Closure System and in Ecuador for the ZYLOX Phoenix Peripheral Fibered Detachable Coil Occlusion System. The company maintains a strong presence in Europe through ongoing market studies and participation in industry conferences like LINC 2025, enhancing its brand visibility.
Commitment to Quality and Innovation
Zylox-Tonbridge is steadfast in its commitment to "Innovation for Quality Life." By leveraging its full-spectrum product portfolio and efficient operational practices, the company aims to solidify its position in the market and facilitate ongoing international growth. The focus remains on delivering solutions with clinical value, paving the way for sustainable growth and contributions to global healthcare innovations.
Frequently Asked Questions
What were Zylox-Tonbridge's revenue growth figures for 2025?
The company reported a revenue growth of 31.7% for the first half of 2025, reaching RMB 482 million.
How much did net profit increase for Zylox-Tonbridge?
Net profit surged by 76%, exceeding RMB 121 million.
What are some key products driving Zylox-Tonbridge's growth?
Key products include the SilverSnake Intermediate Catheter Series and the Kylin Flow Diverter, among others.
In how many countries has Zylox-Tonbridge commercialized its products?
The company has commercialized 22 products across 27 countries and regions.
What is Zylox-Tonbridge's mission statement?
The company is dedicated to "Innovation for Quality Life", emphasizing clinical value and healthcare solutions.
